石明

肝膽腫瘤手術、介入、靶向免疫治療，尤擅長早期肝癌的微創手術治療、中期肝癌的介入治療、晚期肝癌的基因精準醫療 ^[1] 

黃埔院區： 週二上午 ^[1] 

雜誌《實用癌症雜誌》，編委 ^[1] 

1994年於中山醫科大學醫療系本科畢業。2005年於中山大學博士研究生畢業。2008到2009年於德國Diakonie羅騰堡醫院進修普外科和腹腔鏡學習。2012年在新加坡國立癌症中心進行基因精準醫療研究。 ^[1] 

主要從事肝癌的綜合治療，包括：外科治療、介入治療、靶向治療、免疫治療等，及相應基礎研究。近年來致力於優化中晚期肝癌綜合治療的策略。以通訊作者在JAMA Oncol、J Natl Cancer Inst、Hepatology等雜誌上發表多篇論著。特別是揭示了動脈化療是決定介入治療( TACE) 療效的關鍵因素，並提出了肝動脈灌注化療（HAIC）新方案，在歐洲腫瘤年會（ESMO 2020）做了口頭報告。進而提出了HAIC+靶向藥物+免疫治療的聯合治療方案。在基礎研究方面致力於闡明瞭新的分子指標預測肝癌耐藥，揭示了新的治療肝癌靶點。上述成果被多項中國和國際指南採納，包括：《原發性肝癌診療規範（2019版）》、《CSCO原發性肝癌診療指南2020》、泛亞太地區肝癌ESMO管理指南（Ann Oncol, 2020）、2012年歐洲肝病協會肝癌處理指南（J hepatol，2012）、美國肝癌放射介入協會指南（J Vasc Interv Radiol，2012）。 ^[1] 

1.2020，國家自然科學基金面上項目，82072610，LncRNA DUBR通過Notch通路調控肝癌細胞乾性及化療耐藥的機制研究

2.2017，國家重點研發計劃，項目名：抗病毒天然免疫、炎症與癌變機制，課題名：組織免疫（炎性）微環境調控腫瘤發生和發展的機制（2017YFA0505803）

3.2016，國家傑出青年科學基金，81625017，腫瘤學（消化系統腫瘤）

4.2015，國家自然科學基金面上項目，81572385，MEP1A 促進肝細胞癌轉移的作用和機制研究

5.2013，國家自然科學基金面上項目，81272639，腫瘤相關巨噬細胞介導肝癌動脈生成的機制及其在腫瘤進展中的作用 ^[1] 

1.肝癌多學科治療策略優化的研究與應用（2017.2.1），廣東省科技進步一等獎。

2.肝癌多學科治療策略優化的研究與應用（2017.2.22），教育部科學技術進步獎二等獎。 ^[1] 

（1）He MK, Li QJ, Zou RH, Shen JX, Fang WQ, Tan GS, Zhou YM, Wu XP, Xu L, Wei W, Le Y, Zhou ZG, Zhao M, Guo Y, Guo RP, Chen MS, Shi M（通訊作者）. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncol. 2019;5(7):953-960.

（2）OuYang HY, Xu J, Luo J, Zou RH, Chen K, Le Y, Zhang YF, Wei W, Guo RP, Shi M（通訊作者）. MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma. Hepatology 2016; 63(4): 1227-39.

（3）Shi M（通訊作者）, Lu LG, Fang WQ, et al. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst 2013;105(1):59-68.

（4）Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ, Lau WY, Li JQ. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg 2007; 245:36-43.

（5）Luo J, Peng ZW, Guo RP, Zhang YQ, Li JQ, Chen MS, Shi M（通訊作者）. Hepatic resection versus transarterial lipiodol chemoembolization as the initial treatment for large, multiple and resectable hepatocellular carcinoma: a prospective non-randomized analysis. Radiology 2011; 259:286-95.

（6）He MK, Liang RB, Zhao Y, Xu YJ, Chen HW, Zhou YM, Lai ZC, Xu L, Wei W, Zhang YJ, Chen MS, Guo RP, Li QJ, Shi M（通訊作者）. Lenvatinib, Toripalimab, Plus Hepatic Arterial Infusion Chemotherapy versus Lenvatinib Alone for Advanced Hepatocellular Carcinoma. Ther Adv Med Oncol. 2021; 13: 17588359211002720.

（7）He MK, Liang RB, Zhao Y, Liang RB, Lai ZC, Kan A, Li QJ, Wei W, Zhang YJ, Chen MS, Guo RP, Shi M（通訊作者）. Comparison of HBV Reactivation Between Patients with High HBV-DNA and Low HBV-DNA Loads Undergoing PD-1 Inhibitor and Concurrent Antiviral Prophylaxis. Cancer Immunol Immunother. 2021 Apr 03.

（8）Le Y, Kan A, Li QJ, He MK, Chen HL, Shi M（通訊作者）. NAP1L1 is a prognostic biomarker and contribute to doxorubicin chemotherapy resistance in human hepatocellular carcinoma. Cancer Cell Int. 2019; 19: 228.

（9）Zhang YF, Guo RP, Zou RH, Shen JX, Wei W, Li SH, OuYang HY, Zhu HB, Xu L, Lao XM, Shi M（通訊作者）. Efficacy and safety of preoperative chemoembolization for resectable hepatocellular carcinoma with portal vein invasion: a prospective comparative study. Eur Radiol 2016; 26(7): 2078-88.

（10）Shi M, Chen MS, Sekar K et al. A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma. Eur J Cancer 2014; 50: 928-936.

（11）Zhang YF, Zhou J, Wei W, Zou RH, Chen MS, Lau WY, Shi M（共同通訊作者）, Guo RP: Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making. Br J Cancer 115:1039-1047, 2016

（12）Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS, Shi M（通訊作者）. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol, 2011; 18:413-20.

（13）Zhang YF, Guo RP, OuYang HY, Shen JX, Zhao J, Tan GS, Le Y, Wei W, Shi M（通訊作者）: Target lesion response predicts survival of patients with hepatocellular carcinoma retreated with transarterial chemoembolization. Liver Int 2016;36:1516-24.

（14）He MK, Le Y, Li QJ, Yu ZS, Li SH, Wei W, Guo RP, Shi M（通訊作者）. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. Chin J Cancer 2017; 36(1): 83.

（15）He MK, Zou RH, Wei W, Shen JX, Zhao M, Zhang YF, Lin XJ, Zhang YJ, Guo RP, Shi M（通訊作者）. Comparison of Stable and Unstable Ethiodized Oil Emulsions for Transarterial Chemoembolization of Hepatocellular Carcinoma: Results of a Single-Center Double-Blind Prospective Randomized Controlled Trial. J Vasc Interv Radiol. 2018;29(8):1068-1077 e1062.

（16）He MK, Zou RH, Li QJ, Zhou ZG, Shen JX, Zhang YF, Yu ZS, Xu L, Shi M（通訊作者）. Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis. Cardiovasc Intervent Radiol. 2018 May ;41(5) :734-743. ^[1]